A single-center retrospective observational study found metabolic benefits of tirzepatide for patients with partial lipodystrophy. The study in The Journal of Clinical Endocrinology & Metabolism found reductions in A1C, serum triglycerides and daily insulin requirements with tirzepatide. Median weight loss of 7.9% was reported.
Full Story: Medscape (3/31)